Abstract
Cardiovascular diseases are common and occur mainly in the elderly in whom osteoporotic fractures also are very common. Because of this, it is of importance to establish whether drugs used in the treatment of cardiovascular diseases affect bone, in order to minimise any possible adverse effects. In the majority of studies, treatment with thiazide diuretics, statins, digoxin, angiotensin-converting enzyme (ACE)-inhibitors, and organic nitrates have not been associated with harmful effects on bone. On the contrary, treatment with these drugs may improve bone strength but because there is a lack of randomised controlled trials (RCTs) with fracture as a primary outcome measure, these drugs should not be prescribed for fracture prevention. In RCTs, treatment with loop diuretics have been shown to increase plasma levels of parathyroid hormone and decrease bone mineral density. In epidemiological studies, treatment with loop diuretics as well as treatment with amiodarone has been associated with an increased risk of fracture. In view of the conflicting results from published studies, no conclusions can be drawn on potential bone effects of treatment with oral anticoagulants, β-blockers, and calcium channel blockers.
Keywords: Bone, fracture, diuretics, amiodarone, statins, antiarrhythmics
Current Drug Safety
Title: Cardiovascular Drugs and Bone
Volume: 3 Issue: 3
Author(s): Lars Rejnmark
Affiliation:
Keywords: Bone, fracture, diuretics, amiodarone, statins, antiarrhythmics
Abstract: Cardiovascular diseases are common and occur mainly in the elderly in whom osteoporotic fractures also are very common. Because of this, it is of importance to establish whether drugs used in the treatment of cardiovascular diseases affect bone, in order to minimise any possible adverse effects. In the majority of studies, treatment with thiazide diuretics, statins, digoxin, angiotensin-converting enzyme (ACE)-inhibitors, and organic nitrates have not been associated with harmful effects on bone. On the contrary, treatment with these drugs may improve bone strength but because there is a lack of randomised controlled trials (RCTs) with fracture as a primary outcome measure, these drugs should not be prescribed for fracture prevention. In RCTs, treatment with loop diuretics have been shown to increase plasma levels of parathyroid hormone and decrease bone mineral density. In epidemiological studies, treatment with loop diuretics as well as treatment with amiodarone has been associated with an increased risk of fracture. In view of the conflicting results from published studies, no conclusions can be drawn on potential bone effects of treatment with oral anticoagulants, β-blockers, and calcium channel blockers.
Export Options
About this article
Cite this article as:
Rejnmark Lars, Cardiovascular Drugs and Bone, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699469
DOI https://dx.doi.org/10.2174/157488608785699469 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resistin and Oxidative Stress in Non-Diabetic Obstructive Sleep Apnea Patients with Nocturnal Hypertension
Current Respiratory Medicine Reviews TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Default Mode, Executive Function, and Language Functional Connectivity Networks are Compromised in Mild Alzheimer´s Disease
Current Alzheimer Research Genetic Modifications of Icosahedral Plant Virus-based Nanoparticles for Vaccine and Immunotherapy Applications
Current Protein & Peptide Science Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Therapeutic Effects of Rivastigmine and Alfa-Lipoic Acid Combination in the Charles Bonnet Syndrome: Electroencephalography Correlates
Current Clinical Pharmacology Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Editorial: Glia-Neuron Crosstalk and its Therapeutic Implication in Neuropsychiatric Disorders
Current Neuropharmacology Spatio-Temporal Fluctuations of Neural Dynamics in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Behavioral Experimental Paradigms for the Evaluation of Drug’s Influence on Cognitive Functions: Interpretation of Associative, Spatial/Nonspatial and Working Memory
CNS & Neurological Disorders - Drug Targets Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Lipid-Based Diets Improve Muscarinic Neurotransmission in the Hippocampus of Transgenic APPswe/PS1dE9 Mice
Current Alzheimer Research Biopsychosocial Predictors of Cognitive Impairment in the Elderly: A Case-control Study
Current Psychiatry Research and Reviews Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry β3-Adrenergic Receptors: Really Relevant Targets for Anti-Obesity Drugs?
Current Medicinal Chemistry - Central Nervous System Agents Increased Prevalence of Vestibular Loss in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Towards a Clarification of Terminology in Medicine Taking Behavior: Compliance, Adherence and Concordance are Related Although Different Terms with Different Uses
Current Clinical Pharmacology